An interventional study of Staged in-hospital complete revascularization and Immediate complete revascularization in Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis and Multi Vessel Coronary Artery Disease, sponsored by Chonnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Myocardial Infarction by Chonnam National University Hospital — 7 open to participants now, 8 under way, none of them phase 3. Myocardial Infarction · Chonnam National University Hospital.
Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 with no phase, and was the 6th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →7 of the 12 studies in Myocardial Infarction by Chonnam National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,014 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 860 across the 11 interventional studies, 150 across the 1 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chonnam National University Hospital is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention [PCI] for both infarct-related artery [IRA] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.
Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. In cases of hemodynamically stable ST-segment elevation myocardial infarction (STEMI) and MVD, many studies demonstrated the superiority of complete revascularization (CR) by both one-stage and multistage procedures compared to culprit-only revascularization (COR). The 2017 European Society of Cardiology (ESC) guidelines for STEMI recommend routine revascularization for non infarct-related artery (IRA) lesions before hospital discharge in patients without cardiogenic shock.
However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Only one randomized controlled trial, the SMILE trial (J Am Coll Cardiol 2016;67:264-72), compared one-stage and multi-stage multivessel revascularization (MVR) in these patients. Although the results of most studies analyzing interventional strategies in patients with NSTEMI and MVD showed superior results of MVR compared to COR, they did not provide information about staged revascularization. One-stage MVR was associated with better clinical outcomes compared to multi-stage MVR in the SMILE trial, while one-stage and multi-stage MVR had similar incidences of adverse outcomes in large registry data. Although the 2018 ESC/European Association for Cardio-Thoracic Surgery (EACTS) guidelines for myocardial revascularization recommend complete one-stage revascularization in NSTEMI and MVD, it emphasizes individualization based on clinical status and comorbidities, as well as disease severity. In 2020 ESC guidelines for non-ST-segment elevation acute coronary syndrome, this strategy is maintained. CR during index percutaneous coronary intervention (PCI) is recommended in NSTEMI patients with MVD (class IIb, level B).
Whether to revascularize non-IRA using angiography or fractional flow reserve (FFR) is also problematic. FFR is a useful tool for assessing hemodynamic significance of non-IRA during both acute and subacute stage, and FFR-guided PCI for non-IRA lesion is recommended during index PCI (class IIb, level B). In the SMILE trial, a 25.8% of study patients received FFR-guided PCI for non-IRA. Although FFR is a well-known tool to evaluate significant ischemia of moderate stenosis, the most studies regarding FFR enrolled patients without acute myocardial infarction (AMI).
However, the recommendations in current guidelines, which recommends CR during index PCI, is not sufficiently powered to assess differences in clinical outcomes between interventional strategy. There are also few studies regarding this issue, and discrepancy in clinical outcomes between randomized trial and observational studies. Furthermore, FFR-guided PCI for non-IRA is not mandatory in these studies.
Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (PCI for both IRA and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of FFR, and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-ST-segment elevation myocardial infarction
Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and,
Elevated cardiac biomarkers and,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after percutaneous coronary intervention (PCI) for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Procedure: Staged in-hospital complete revascularization
Non-infarct related artery (IRA) will be revascularized immediately after percutaneous coronary intervention (PCI) for IRA (during index PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Procedure: Immediate complete revascularization
Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Cumulative incidence rate of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization
Composite endpoint of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization at 1 year from baseline
Time frame: Up to 12 months
Rate of contrast-induced nephropathy
Rate of contrast-induced nephropathy during initial hospitalization
Time frame: Up to 12 months
Cumulative incidence rate of all unplanned revascularization
Cumulative incidence rate of all unplanned revascularization at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of target-lesion revascularization
Cumulative incidence rate of target-lesion revascularization at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of target-vessel revascularization
Cumulative incidence rate of target-vessel revascularization at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of non-target vessel revascularization
Cumulative incidence rate of non-target vessel revascularization at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of all-cause death
Cumulative incidence rate of all-cause death at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of cardiac death
Cumulative incidence rate of cardiac death at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of non-cardiac death
Cumulative incidence rate of non-cardiac death at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of non-fatal myocardial infarction
Cumulative incidence rate of non-fatal myocardial infarction at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of hospitalization for unstable angina
Cumulative incidence rate of hospitalization for unstable angina at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of hospitalization for heart failure
Cumulative incidence rate of hospitalization for heart failure at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of definite or probable stent thrombosis
Cumulative incidence rate of definite or probable stent thrombosis at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of ischemic and hemorrhagic stroke
Cumulative incidence rate of ischemic and hemorrhagic stroke at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of major bleeding (BARC [Bleeding Academic Research Consortium] definitions type 3 or 5)
Cumulative incidence rate of major bleeding (BARC \[Bleeding Academic Research Consortium\] definitions type 3 or 5) at each visit
Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Cumulative incidence rate of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization
Composite endpoint of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization at each visit
Time frame: Index admission, 1 month, 6 months, 24 months, 36 months, 48 months, 60 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Aug 2028, 83 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 83 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chonnam National University Hospital